Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.790 +0.350 (+5.43%)
Delayed Quote Updated: 9:39 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
From Emergent BioSolutions Inc.
Via Business Wire
News headline image
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
From Emergent BioSolutions Inc.
Via Business Wire
News headline image
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
From Emergent BioSolutions Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
From Emergent BioSolutions
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
From Emergent BioSolutions
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports First Quarter 2026 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.